Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gardasil Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

NCT05119855
View directory record Official record
Conditions
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions
9vHPV Vaccine, mRNA-1273 Vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 11 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

NCT00513526
View directory record Official record
Conditions
Infection, Precancerous Condition
Interventions
Gardasil
Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

NCT00604175
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent HPV vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

NCT00573651
View directory record Official record
Conditions
Arthritis
Interventions
Blood Draws for Serum Titers
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 5, 2026, 12:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Memory After Papillomavirus Vaccination

NCT01505049
View directory record Official record
Conditions
Healthy Volunteers
Interventions
quadrivalent HPV vaccine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Sep 5, 2026, 12:42 PM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)

NCT06688058
View directory record Official record
Conditions
Healthy
Interventions
V540D, GARDASIL®9
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Hollywood, Florida • Savannah, Georgia • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*

NCT07339163
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis (RRP)
Interventions
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
Biological
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessing Durable Antibody Response to HPV Vaccination

NCT05031078
View directory record Official record
Conditions
HPV
Interventions
Gardasil-9, Lidocaine injections
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making

NCT00807898
View directory record Official record
Conditions
Cervical Cancer
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
13 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 5, 2026, 12:42 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

NCT05672927
View directory record Official record
Conditions
Immunization, HPV Infection, Human Papillomavirus
Interventions
9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
27 Years to 45 Years · Female only
Enrollment
618 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

NCT00572832
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 23 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 5, 2026, 12:42 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

NCT04206813
View directory record Official record
Conditions
HPV Infection
Interventions
Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898
View directory record Official record
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions
Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 5, 2026, 12:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Investigating HPV Vaccination Uptake in Adults Aged 18-35 Seeking Care at a Health Clinic in Rural Mississippi

NCT05658198
View directory record Official record
Conditions
Human Papillomavirus Vaccination
Interventions
Counseling
Behavioral
Lead sponsor
Plan A Health, Inc
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louise, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females

NCT00813319
View directory record Official record
Conditions
Vaccination
Interventions
Girls OnGuard
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Gardasil Vaccination in Post Stem Cell Transplant Patients

NCT01092195
View directory record Official record
Conditions
Gardasil Vaccine, Stem Cell Transplant, Immunogenicity
Interventions
Gardasil
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 5, 2026, 12:42 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

NCT02568566
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
9 Years to 11 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

NCT06229353
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Gardasil 9
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Not applicable Interventional Results available

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

NCT00941889
View directory record Official record
Conditions
HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions
Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

NCT02199691
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 5, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063
View directory record Official record
Conditions
Childhood Cancer, Multiple Diseases
Interventions
Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 5, 2026, 12:42 PM EDT